Table 1.

Characteristics of included patients at baseline (n = 15).

Variables	Exercise (n = 8)	Control (n = 7)
Age, years	64 ± 5.8	65 ± 4.7
Female sex, n	5 (62.5%)	5 (71.4%)
Body mass index, kg/m2	24.1 ± 4.4	24.2 ± 1.9
Smocking history
Never	1 (12.5%)	0 (0.0%)
Former	5 (62.5%)	4 (57.1%)
Current	2 (25.0%)	3 (42.9%)
Pack-years	35 ± 19.9	38 ± 13.8
Level of education
10th grade or less	2 (25.0%)	2 (28.6%)
Vocational education	2 (25.0%)	2 (28.6%)
Further education (<3 years)	2 (25.0%)	0 (0.0%)
Higher education (3–4 years)	2 (25.0%)	1 (14.3%)
Master degree (5 years or more)	0 (0.0%)	2 (28.6%)
Stage
IIIa	3 (37.5%)	2 (28.6%)
IIIb	4 (50.0%)	4 (57.1%)
IV	1 (12.5%)	1 (14.3%)
Pathology
Adenocarcinoma	5 (62.5%)	4 (57.1%)
Squamous carcinoma	3 (37.5%)	3 (42.9%)
Cytostatica
Cisplatin + vinorelbin	6 (75.0%)	6 (85.7%)
Carboplatin + vinorelbin	2 (25.0%)
Pulmonary function
Predicted FEV1, L	2.2 ± 0.74	2.3 ± 0.65
Predicted FEV1, %	86.4 ± 26.8	98.6 ± 23.8
Physiological measurements
$\dot{\text{V}}{\text{O}}_{2\text{peak}}$, ml O2/min	1.328 ± 0.458	1.460 ± 0.431
$\dot{\text{V}}{\text{O}}_{2\text{peak}}$, ml O2/kg/min	20 ± 3.6	22 ± 6.2
iPPO, W	90 ± 29	101 ± 57
6MWD, m	437 ± 126	515 ± 124
Systolic blood pressure, mmHg	138 ± 21	131 ± 16
Diastolic blood pressure, mmHg	85 ± 16	80 ± 9
HRmax, beats/min	153 ± 18	144 ± 22
HRrest, beats/min	91 ± 17	72 ± 9

Data are presented as mean ± SD or n (%). Only 7 patients are included in HR_max for EXE. Six patients are included in cytostatica for CON. FEV₁: forced expired volume in 1 s; $\dot{\text{V}}{\text{O}}_{2\text{peak}}$: maximal oxygen uptake; iPPO: incremental peak power output; 6MWD: 6 min walk distance; HR: heart rate.